Funders · Entity Annotation Prototype (beta)

2articles mentioning funders

2funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Norwegian Medical Products Agency ×

Norwegian Medical Products Agency

This funder is selected. Its supporting articles are shown below.

Norwegian Medical Products Agency2

Articles mentioning Norwegian Medical Products Agency

2 articles · page 1 of 1

Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway—the DEAK study

bmjopen · abstract · 2026-06-18 · 1 matching annotations

83.1%

Norwegian Medical Products Agency dapagliflozin chronic kidney disease type 2 diabetes

…tocol (EudraCT number: 2022-002428-10) has been approved by the Norwegian Medical Products Agency, the Regional Committee for Medical Research Ethics in Southeas…

Impact of a patient-centred levothyroxine decision support tool on rapid achievement of target dosage and improved patient outcomes: protocol for a randomised controlled trial

bmjopen · abstract · 2026-03-18 · 1 matching annotations

83.3%

Norwegian Medical Products Agency CIV-23-02-042436 levothyroxine University Hospital of North Norway DST thyroidectomy

…ork.Ethics and dissemination The study has been approved by the Norwegian Medical Products Agency (CIV-23-02-042436), The Norwegian Ethics Committee for Clinical…

Browse funders

Norwegian Medical Products Agency

Articles mentioning Norwegian Medical Products Agency

Impact of a patient-centred levothyroxine decision support tool on rapid achievement of target dosage and improved patient outcomes: protocol for a randomised controlled trial